Exagen: A Small Diagnostics Company Approaching An Inflection Point (NASDAQ:XGN)
· seekingalpha.com
Exagen (XGN) Buy: accelerating revenue, improving ASPs, and path to breakeven by 2027.
Exagen (NASDAQ: XGN ) is becoming a very interesting diagnostics company as revenue growth accelerates, average selling prices are improving, and management mov...